Filing Details

Accession Number:
0001104659-19-076864
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-30 19:01:06
Reporting Period:
2019-12-27
Accepted Time:
2019-12-30 19:01:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1270073 Intercept Pharmaceuticals Inc. ICPT Pharmaceutical Preparations (2834) 223868459
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1493811 Christian Weyer C/O Intercept Pharmaceuticals, Inc.
10 Hudson Yards, Floor 37
New York NY 10001
Evp, Research & Development No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-12-27 416 $59.12 15,705 No 4 M Direct
Common Stock Acquisiton 2019-12-27 54 $58.74 15,759 No 4 M Direct
Common Stock Disposition 2019-12-27 1,581 $123.24 14,178 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option to Purchase Common Stock Disposition 2019-12-27 416 $0.00 416 $59.12
Common Stock Option to Purchase Common Stock Disposition 2019-12-27 54 $0.00 54 $58.74
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
17,692 2027-11-27 No 4 M Direct
2,883 2028-02-05 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
  2. The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Start Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Start Date was November 27, 2017.
  3. The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Start Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Start Date was January 1, 2018.